IXICO (IXI) Stock Overview
Provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IXI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
IXICO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.073 |
| Beta | 0.40 |
| 1 Month Change | -12.77% |
| 3 Month Change | -4.65% |
| 1 Year Change | -12.77% |
| 3 Year Change | -61.68% |
| 5 Year Change | -88.48% |
| Change since IPO | -82.63% |
Recent News & Updates
Recent updates
Is IXICO plc (LON:IXI) Potentially Undervalued?
Sep 30
Is It Time To Consider Buying IXICO plc (LON:IXI)?
Apr 13If You Like EPS Growth Then Check Out IXICO (LON:IXI) Before It's Too Late
Feb 25Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Nov 20Should You Think About Buying IXICO plc (LON:IXI) Now?
Oct 25Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Aug 11Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Apr 17IXICO plc (LON:IXI) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Mar 24At UK£1.04, Is It Time To Put IXICO plc (LON:IXI) On Your Watch List?
Mar 22Does IXICO's (LON:IXI) Statutory Profit Adequately Reflect Its Underlying Profit?
Feb 22Did Business Growth Power IXICO's (LON:IXI) Share Price Gain of 146%?
Feb 01
Will Weakness in IXICO plc's (LON:IXI) Stock Prove Temporary Given Strong Fundamentals?
Jan 09I Ran A Stock Scan For Earnings Growth And IXICO (LON:IXI) Passed With Ease
Dec 22Who Has Been Selling IXICO plc (LON:IXI) Shares?
Dec 04What Does IXICO plc's (LON:IXI) Share Price Indicate?
Jul 06Shareholder Returns
| IXI | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -8.9% | -5.1% | 1.9% |
| 1Y | -12.8% | 5.0% | 21.2% |
Return vs Industry: IXI underperformed the UK Life Sciences industry which returned 5% over the past year.
Return vs Market: IXI underperformed the UK Market which returned 21.2% over the past year.
Price Volatility
| IXI volatility | |
|---|---|
| IXI Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 10.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: IXI has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: IXI's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 79 | Bram Goorden | ixico.com |
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services.
IXICO plc Fundamentals Summary
| IXI fundamental statistics | |
|---|---|
| Market cap | UK£9.50m |
| Earnings (TTM) | -UK£1.65m |
| Revenue (TTM) | UK£6.53m |
Is IXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXI income statement (TTM) | |
|---|---|
| Revenue | UK£6.53m |
| Cost of Revenue | UK£3.35m |
| Gross Profit | UK£3.18m |
| Other Expenses | UK£4.83m |
| Earnings | -UK£1.65m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 48.71% |
| Net Profit Margin | -25.27% |
| Debt/Equity Ratio | 0% |
How did IXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 21:24 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IXICO plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Hans Bjorn Bostrom | Edison Investment Research |
| Tara Raveendran | Shore Capital Group Ltd |